STAT1d
Pharmalittle: We’re reading about possible HIV prevention cuts, FDA warning an Africa drugmaker, and more
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
STAT9h
Biotech stocks get boost from Fed rate outlook
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...
Healio6d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
BioSpace1d
Trump Eyes Steep Cuts to CDC HIV Prevention Program
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
The Scientist8d
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...